ER+ breast cancers, which are classified as luminal subtypes LuminalA (LumA) and LuminalB (LumB), are most commonly treated using agents inhibiting the estrogen receptor or hormone levels [8, 9]. The gene discussed is ESR1; the disease is breast cancer.